AGIO Agios Pharmaceuticals Inc.

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021

CAMBRIDGE, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism to treat cancer and genetically defined diseases, today announced that the company is scheduled to present at the virtual 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021 at 10:50 a.m. ET.

A live webcast of the presentation and breakout session can be accessed under "Events & Presentations" in the Investors section of the company's website at A replay of the webcast will be archived on the Agios website for at least two weeks following the presentation.

About Agios

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and genetically defined diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development. For more information, please visit the company's website at .

Contacts

Investors:

Holly Manning, 617-844-6630

Director, Investor Relations

Media:

Jessica Rennekamp, 857-209-3286

Associate Director, Corporate Communications



EN
05/01/2021

Underlying

AGIOAgios Pharmaceuticals Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agios Pharmaceuticals Inc.

 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat...

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia PDUFA goal date extended by three months from September 7, 2025, to December 7, 2025 CAMBRIDGE, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for the supplemental New Drug Application (sNDA) of PYRUKYND® (mitapivat)...

September 4, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in S...

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia First regulatory approval for PYRUKYND in thalassemia, evaluated under SFDA’s Breakthrough Medicines Program Agios partnered with NewBridge Pharmaceuticals, a regional specialty company focused on the Middle East and North Africa, in 2024 to manage PYRUKYND commercialization in the Gulf Region  CAMBRIDGE, Mass., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases...

August 4, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Reports Second Quarter 2025 Financial Results and Provides Busin...

Agios Reports Second Quarter 2025 Financial Results and Provides Business Update $12.5 million in second quarter PYRUKYND® (mitapivat) net revenues; ended second quarter with $1.3 billion dollars in cash, cash equivalents and marketable securitiesPYRUKYND sNDA for thalassemia under active review, with FDA PDUFA goal date of September 7, 2025Topline results from RISE UP Phase 3 trial of mitapivat in sickle cell disease on track by year-end with potential U.S. commercial launch in 2026Dosed first patient in the tebapivat Phase 2 sickle cell disease trial and received IND clearance for AG-236 ...

July 31, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios to Host Webcast Conference Call of Second Quarter Financial Resu...

Agios to Host Webcast Conference Call of Second Quarter Financial Results on July 31, 2025 at 8:00am ET CAMBRIDGE, Mass., July 14, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the company will host a conference call and live webcast on Thursday, July 31, 2025, at 8:00 a.m. ET to report its second quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company’s website () und...

July 14, 2025 1 EN
 PRESS RELEASE
Free
AGIO Agios Pharmaceu...

Agios Appoints Dr. Jay Backstrom to Board of Directors

Agios Appoints Dr. Jay Backstrom to Board of Directors CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. “We are thrilled to wel...

July 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch